Share

December 15, 2015; 85 (24) Editorial

Is more really better?

The effect of enrollment volume on outcomes for medical therapies

Thomas Jeerakathil, Lars Marquardt
First published November 11, 2015, DOI: https://doi.org/10.1212/WNL.0000000000002198
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
78

Share

Article Information

vol. 85 no. 24 2086-2087
DOI: 
https://doi.org/10.1212/WNL.0000000000002198
PubMed: 
26561293
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 11, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Thomas Jeerakathil, MD, MSc and
    2. Lars Marquardt, MD, DPhil
  1. Thomas Jeerakathil, MD, MSc and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) Alberta Health Services, The Stroke Action Plan, Project Lead, 2013-2015 2) Canadian Institutes of Health Research, Canadian Stroke Network, Heart and Stroke Foundation of Canada. The ASPIRE TIA Triaging Project. Project co-principal applicant. 2008-2015. 3) Alberta Innovates Health Solutions (AIHS). Quality Improvement and Research in Stroke (QUiCR). Collaborative Co-Chair. 2014-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) Heart and Stroke Foundation of Canada 2) The Canadian Institutes for Health Research 3) The Canadian Stroke Network 4) Alberta Innovates Health Solutions

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lars Marquardt, MD, DPhil
    3. Scientific Advisory Boards:

    1. (1) Boehringer Ingelheim

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Boehringer Ingelheim, speaker honoraria and travel costs (2) Pfizer, speakers honoraria (3) Bayer, travel costs (4) BMS, speakers honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Neurology, Department of Medicine (T.J.), University of Alberta, Edmonton, Canada; and the Department of Neurology and Neurogeriatrics (L.M.), Asklepios Klinik Wandsbek, Hamburg, Germany.
  1. Correspondence to Dr. Jeerakathil: thomasj{at}ualberta.ca
View Full Text

Article usage

Article usage: November 2015 to February 2023

AbstractFullPdfSource
Nov 2015161119Highwire
Dec 20154042841Highwire
Jan 20164878Highwire
Feb 20161802Highwire
Mar 20161530Highwire
Apr 2016700Highwire
May 20161400Highwire
Jun 20161111Highwire
Jul 2016800Highwire
Aug 20161000Highwire
Sep 20163510Highwire
Oct 20161600Highwire
Nov 20161300Highwire
Dec 20161400Highwire
Jan 20171600Highwire
Feb 2017600Highwire
Mar 2017700Highwire
Apr 20171000Highwire
May 20171200Highwire
Jun 2017600Highwire
Jul 2017200Highwire
Aug 2017100Highwire
Sep 2017100Highwire
Oct 2017401Highwire
Nov 2017600Highwire
Dec 2017700Highwire
Jan 2018400Highwire
Feb 2018100Highwire
Mar 20181401Highwire
Apr 2018100Highwire
May 2018300Highwire
Jun 2018300Highwire
Jul 2018600Highwire
Aug 2018500Highwire
Sep 2018200Highwire
Oct 2018300Highwire
Nov 2018600Highwire
Dec 2018600Highwire
Feb 2019700Highwire
Mar 2019200Highwire
Apr 2019100Highwire
May 2019100Highwire
Jun 2019600Highwire
Jul 2019300Highwire
Aug 2019400Highwire
Sep 2019900Highwire
Oct 2019601Highwire
Nov 20191200Highwire
Dec 2019600Highwire
Jan 2020900Highwire
Feb 2020400Highwire
Mar 2020700Highwire
Apr 2020100Highwire
May 2020201Highwire
Jun 2020600Highwire
Jul 20201500Highwire
Aug 2020301Highwire
Sep 2020100Highwire
Oct 2020400Highwire
Nov 2020510Highwire
Jan 2021400Highwire
Feb 20211300Highwire
Mar 20211000Highwire
Apr 2021200Highwire
May 2021500Highwire
Jun 2021300Highwire
Jul 2021600Highwire
Aug 20211010Highwire
Sep 2021100Highwire
Oct 2021900Highwire
Nov 20211500Highwire
Dec 2021900Highwire
Jan 2022500Highwire
Feb 20221400Highwire
Mar 2022700Highwire
Apr 20221000Highwire
May 2022800Highwire
Jun 2022301Highwire
Jul 2022701Highwire
Aug 2022500Highwire
Sep 2022600Highwire
Oct 2022400Highwire
Nov 2022500Highwire
Dec 2022610Highwire
Jan 2023200Highwire
Feb 2023500Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles